An Affinity Threshold for Maximum Efficacy in Anti-PD-1 Cancer Immunotherapy

Monoclonal antibodies (mAbs) targeted to the programmed cell death protein 1 (PD-1) remain the most prevalent cancer immunotherapy both as a monotherapy and in combination with additional therapies. Despite the extensive success of anti-PD-1 mAbs in the clinic, the experimental relationship between...

Description complète

Détails bibliographiques
Auteur principal: Cowles, Sarah Clare
Autres auteurs: Wittrup, K. Dane
Format: Thèse
Publié: Massachusetts Institute of Technology 2022
Accès en ligne:https://hdl.handle.net/1721.1/144968
https://orcid.org/ 0000-0002-2246-6333